Transparancy leading to massive reserch opportunities

With Professor Robert Clancy.

Link to Quadrant,

Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-up

Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults

Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

COVID-19 mRNA VACCINES: THE PROBLEM THAT WON’T GO AWAY.

Emeritus Professor Robert Clancy AM

This month we ‘celebrate’ 5 years since the covid pandemic began in Australia. This is the 10th article I have written for Quadrant on covid pandemic management. Prior to the pandemic my 300+ publications had been in peer reviewed medical journals. Most reported research on airway immune protection which has been my passion for 50 years. In 2019 the University of Newcastle awarded me a Doctor of Science for this work (I was informed that this was the first such award given by the University). My point is that in 2020 with the appearance of SARS-CoV-2 (the virus causing Covid-19), entirely by circumstance, I was as well placed as anyone to understand this new airway infection, its pathogenesis and its management. Specifically, the likely place for vaccination in the control of the pandemic. That is what I did.